Eric Wang

Eric Wang

Auto-generated profile, based on publicly available information

Eric Wang

The Jackson Laboratory for Genomic Medicine

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AYAnna Yeaton
Anna Yeaton
GCGeraldine Cayanan
Geraldine Cayanan
SLSanam Loghavi
Sanam Loghavi
IDIgor Dolgalev
Igor Dolgalev
ELEmmett M. Leddin
Emmett M. Leddin
MGMaria Guillamot
Maria Guillamot
Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated preleukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation frequently found in patients with CH and leukemia. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid leukemia (AML). Using single-cell transcriptomic profiling of the bone marrow, we show that disease progression in aged animals correlates with an enhanced inflammatory response and the emergence of an aberrant inflammatory monocytic cell population. The gene signature characteristic of this inflammatory population is associated with poor prognosis in patients with AML. Our study illustrates an example of collaboration between a genetic lesion found in CH and inflammation, leading to transformation and the establishment of blood neoplasms. Significance: Progression from a preleukemic state to transformation, in the presence of TET2 mutations, is coupled with the emergence of inflammation and a novel population of inflammatory monocytes. Genes characteristic of this inflammatory population are associated with the worst prognosis in patients with AML. These studies connect inflammation to progression to leukemia. See related commentary by Pietras and DeGregori, p. 2234 . This article is highlighted in the In This Issue feature, p. 2221

22 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
PTPalaniraja Thandapani
Palaniraja Thandapani
AKAndreas Kloetgen
Andreas Kloetgen
MWMatthew T. Witkowski
Matthew T. Witkowski
CGChristina Glytsou
Christina Glytsou
ALAnna K. Lee
Anna K. Lee
IAIannis Aifantis
Iannis Aifantis

22 December 2022 in Cancer Cell
Verified
Journal Article
Open access
EWEric Wang
Eric Wang
JPJose Mario Bello Pineda
Jose Mario Bello Pineda
WKWon Jun Kim
Won Jun Kim
SCSisi Chen
Sisi Chen
JBJessie Bourcier
Jessie Bourcier
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Therapy resistance is a major challenge in the treatment of cancer. Here, we performed CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to identify genomic determinants of drug response. Our screens uncover a selective dependency on RNA splicing factors whose loss preferentially enhances response to the BCL2 inhibitor venetoclax. Loss of the splicing factor RBM10 augments response to venetoclax in leukemia yet is completely dispensable for normal hematopoiesis. Combined RBM10 and BCL2 inhibition leads to mis-splicing and inactivation of the inhibitor of apoptosis XIAP and downregulation of BCL2A1, an anti-apoptotic protein implicated in venetoclax resistance. Inhibition of splicing kinase families CLKs (CDC-like kinases) and DYRKs (dual-specificity tyrosine-regulated kinases) leads to aberrant splicing of key splicing and apoptotic factors that synergize with venetoclax, and overcomes resistance to BCL2 inhibition. Our findings underscore the importance of splicing in modulating response to therapies and provide a strategy to improve venetoclax-based treatments.

29 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SCSisi Chen
Sisi Chen
RVRahul S. Vedula
Rahul S. Vedula
ACAntonio Cuevas-Navarro
Antonio Cuevas-Navarro
BLBin Lu
Bin Lu
SHSimon J. Hogg
Simon J. Hogg
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adapter of a Cullin-3 RING E3 ubiquitin ligase complex responsible for the degradation of RAS GTPases. In parallel, dysregulated LZTR1 expression via aberrant splicing and mutations was identified in clonal hematopoietic conditions. Here we identify that loss of LZTR1, or leukemia-associated mutants in the LZTR1 substrate and RAS GTPase RIT1 that escape degradation, drives hematopoietic stem cell (HSC) expansion and leukemia in vivo. Although RIT1 stabilization was sufficient to drive hematopoietic transformation, transformation mediated by LZTR1 loss required MRAS. Proteolysis targeting chimeras (PROTAC) against RAS or reduction of GTP-loaded RAS overcomes LZTR1 loss-mediated resistance to FLT3 inhibitors. These data reveal proteolysis of noncanonical RAS proteins as novel regulators of HSC self-renewal, define the function of RIT1 and LZTR1 mutations in leukemia, and identify means to overcome drug resistance due to LZTR1 downregulation. Significance: Here we identify that impairing proteolysis of the noncanonical RAS GTPases RIT1 and MRAS via LZTR1 downregulation or leukemia-associated mutations stabilizing RIT1 enhances MAP kinase activation and drives leukemogenesis. Reducing the abundance of GTP-bound KRAS and NRAS overcomes the resistance to FLT3 kinase inhibitors associated with LZTR1 downregulation in leukemia. This article is highlighted in the In This Issue feature, p. 2221

15 November 2022 in Blood
Verified
Journal Article
Open access
SMSkye Montoya
Skye Montoya
JBJessie Bourcier
Jessie Bourcier
MTMeghan Caitlin Thompson
Meghan Caitlin Thompson
MNMark Noviski
Mark Noviski
MTMay Tan
May Tan
JTJustin Taylor
Justin Taylor

13 October 2023 in Trends in Cancer
Verified
Journal Article
Closed access
ACAlexander Calderon
Alexander Calderon
CHCuijuan Han
Cuijuan Han
SKSadik Karma
Sadik Karma
EWEric Wang
Eric Wang